Evaluation of a Pharmacist-Managed Diabetes Transitions of Care Medication Management Clinic.

Purpose: The purpose of this study was to determine the impact of a pharmacist-managed transitions of care (TOC) clinic on outcomes in a posthospitalization population with diabetes.

Methods: A retrospective single center cohort study utilized electronic health records to identify discharged patients followed by the inpatient endocrinology team. The primary outcome was 30-day readmission rates in the target population.

Nebulized medications in the emergency department: A narrative review of nontraditional agents.

Purpose: This article summarizes emerging nontraditional therapies administered via the nebulization route for use in the emergency department (ED).

Summary: Although traditional routes of medication administration (eg, intravenous) have been the mainstay of administration modalities for decades, these routes may not be appropriate for all patients. Nowhere is this more readily apparent than in the ED setting, where patients with a variety of presentations receive care.

Power of Prevention: The Pharmacist's Role in Prediabetes Management.

Although it is known that the National Diabetes Prevention Program can significantly reduce the incidence of type 2 diabetes in individuals identified as being at high risk, there remains a large number of Americans in underserved areas who are not being reached. The field of pharmacy has the potential to bridge this gap and aid the United States in more comprehensively addressing its national diabetes health crisis, thus changing the future of diabetes for the better.

Comprehensive Geriatric Assessment for Trauma: Operationalizing the Trauma Quality Improvement Program Directive.

Elderly patients are the fastest growing trauma demographic and present some of the most complicated clinical challenges. This feasibility study employed observational data from a geriatric cohort. Comprehensive geriatric assessments (CGAs) were performed biweekly on eligible patients, 65 years or older, who met screening criteria.

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview.

Proprotein convertase subtilisin/kexin type 9 inhibitors serve as a valuable addition to the armamentarium of lipid-lowering agents and have promising potential. By inhibiting the proprotein convertase subtilisin/kexin type 9 enzyme, this novel molecule leads to increased low-density lipoprotein receptor density and decreased circulation of low-density lipoprotein. The fact the agent is a monoclonal antibody has led to limited drug interactions and minimized adverse drug events.

Complements Are Not Always a Good Thing: Novel Therapies for Angioedema.

Hereditary angioedema attacks are rare, but emergency care providers must be aware of the clinical presentation and treatment of these patients because the emergency department remains the most common setting where these patients seek treatment. If providers are not aware of the past medical history of these patients, they are likely to receive standard therapies for respiratory distress and anaphylaxis including antihistamines, corticosteroids, and epinephrine. However, these medications may not work in these patients, given the pathophysiology of their underlying disease.

A multiple-dose phase I study of intranasal hydromorphone hydrochloride in healthy volunteers.

We evaluated the pharmacokinetics, tolerability, and safety of 1 and 2 mg of intranasal hydromorphone hydrochloride in an open-label, single- and multiple-dose study. This Phase I study was conducted in 24 healthy volunteers (13 men and 11 women). Intranasal doses were delivered as 0.